Doxorubicin plus dacarbazine (DoDa), doxorubicin plus ifosfamide (DI) or doxorubicin alone (Do) as first line treatment for advanced leiomyosarcoma (LMS): A retrospective study from the EORTC Soft Tissue and Bone Sarcoma Group (STBSG).
暂无分享，去创建一个
J. Blay | S. Litière | H. Gelderblom | A. Gronchi | B. Vincenzi | A. Czarnecka | S. Piperno-Neumann | D. Katz | R. Flippot | J. Broto | G. Grignani | B. Kasper | F. Mazzeo | F. Duffaud | D. Stark | A. Tuchscherer | R. Sanfilippo | L. D'ambrosio | N. Touati | W. Sents